BlackRock Group’s Harvard Bioscience HBIO Stock Holding History

BlackRock Group’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$81K	Hold	2,642	–	–	﹤0.01%	2864
2016 Q3	$72K	Hold	2,642	–	–	﹤0.01%	2870
2016 Q2	$76K	Hold	2,642	–	–	﹤0.01%	2847
2016 Q1	$80K	Hold	2,642	–	–	﹤0.01%	2820
2015 Q4	$92K	Hold	2,642	–	–	﹤0.01%	2704
2015 Q3	$100K	Sell	2,642 -3,049	-54%	-$142K	﹤0.01%	2708
2015 Q2	$324K	Sell	5,691 -9,448	-62%	-$538K	﹤0.01%	2425
2015 Q1	$881K	Sell	15,139 -9,500	-39%	-$510K	﹤0.01%	1939
2014 Q4	$1.4M	Sell	24,639 -511	-2%	-$24.4K	﹤0.01%	1678
2014 Q3	$1.03M	Buy	+25,150	New	+$1.16M	﹤0.01%	1765
2013 Q4	–	Sell	-13,446	Closed	-$536K	–	2720
2013 Q3	$536K	Buy	+13,446	New	+$529K	﹤0.01%	2209

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock Group's HBIO Position: Q4 2016 in Review

BlackRock Group held its Harvard Bioscience (HBIO) position steady in Q4 2016 at 2,642 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #2864.

BlackRock Group first reported a position in HBIO in Q3 2013 and has held it in 11 quarters since. The position peaked at $1.4M in Q4 2014. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2016.

BlackRock Group held 2,642 shares of Harvard Bioscience worth $81K as of Q4 2016.
BlackRock Group left its Harvard Bioscience share count unchanged in Q4 2016.
Harvard Bioscience made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2864 holding.
BlackRock Group first reported a position in Harvard Bioscience in Q3 2013 and has held it in 11 quarters since.
BlackRock Group's Harvard Bioscience position peaked at $1.4M in Q4 2014.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.